Alemtuzumab Induction via Intravenous vs. Subcutaneous Administration in Pediatric Kidney Transplantation. | ScholarDeck

Paper

Alemtuzumab Induction via Intravenous vs. Subcutaneous Administration in Pediatric Kidney Transplantation.

New research · Pediatrics

Pediatric transplantation · 2w

Cohort studyPediatric transplantation· Aug 2026

Alemtuzumab Induction via Intravenous vs. Subcutaneous Administration in Pediatric Kidney Transplantation.

H Pizzo, A Barbera, K Westreich … D Puliyanda

Read paper

Pediatric NephrologyCohort studyTreatmentQ2IF 1.5

Subcutaneous alemtuzumab dosed higher than IV, causing more leukopenia in children

Alemtuzumab Induction via Intravenous vs. Subcutaneous Administration in Pediatric Kidney Transplantation.

H Pizzo … D Puliyanda

Pediatric transplantation · Aug 2026 · Q2 in Pediatrics

Background

Alemtuzumab is an induction immunosuppressive agent effective in preventing hyperacute rejection; however, it can result in prolonged lymphocyte depletion.

Methods

A multicenter analysis of 119 patients < 21 years old who received alemtuzumab induction immunosuppression.

n = 119 patients

Results

subcutaneous dosing averaged higher than IV, driving more leukopenia

0.57mg/kg

0.36mg/kg

More results

A total of 83 and 36 recipients received alemtuzumab IV and SQ, respectively.

SQ group was slightly older, 14.0 y.

10 (12.1%) (p = 0.002).

0.36 mg/kg (SD 0.18 mg), respectively (p = 0.0001 and p < 0.0001).

“

Conclusion · 1 of 2

Despite the higher dose of alemtuzumab and rates of leukopenia in the SQ group, there were no other differences in tolerability and outcomes compared to IV alemtuzumab.

Conclusion · 2 of 2

Overall, alemtuzumab is well tolerated during the first year post-transplant as an induction immunosuppression agent in the pediatric population.

Read paper